Studies on bioactive peptides report reduced joint discomfort and improved mobility compared to control groups, although results vary by compound
Fewer degranulation events mean less release of all inflammatory mediators, not just histamine
Sensitive patients may react poorly: Individuals with MCAS, histamine intolerance, CIRS, medication sensitivity, neurological sensitivity, or high inflammatory burden may need extra caution, as it can cause overstimulation
Huge green flag
Comparative effectiveness research with established therapies would help determine the relative benefits and risks of these peptides compared to current standard treatments and would inform evidence-based treatment decisions
We frequently reach across the aisle and gain intelligence on corporate bonds from taxable fixed income analysts, which helps us gain a holistic perspective on the fixed income markets